Border

Vertex Expands Rare Disease Portfolio with $10B Crinetics Acquisition

Border

Vertex Pharmaceuticals is strengthening its position in rare diseases with its $10 billion acquisition of Crinetics Pharmaceuticals. The deal adds Crinetics’ commercial and late-stage endocrinology assets, including treatments for acromegaly and congenital adrenal hyperplasia, while expanding Vertex’s pipeline beyond cystic fibrosis. The acquisition reflects the continued momentum in life sciences M&A as companies invest in innovative therapies, diversify their portfolios, and drive long-term growth.

Click here to read the entire article.

Did you find this helpful? Share with your network!

More Tips From The Bandish Group

Border Line

The Skills Employees Need to Succeed in the Age of AI

◆

Artificial intelligence is changing the workplace, but the skills employees need in the age of AI are not necessarily new.…

#455: Interview Questions for Hiring Managers: How to Identify the Right Candidate

◆

An effective interview is about more than confirming what’s already listed on a candidate’s resume. It’s an opportunity for hiring…

Scroll to Top